ALIA-1758 Safety Study in Healthy Participants
Trial Summary
What is the purpose of this trial?
This is a Phase 1, first in human (FIH), double-blind, placebo-controlled, single ascending dose (SAD) trial to assess the safety, tolerability, and pharmacokinetics (PK) of intravenously (IV) or subcutaneously (SC) injected ALIA-1758 in healthy male and female participants.
Research Team
J. Michael Ryan, M.D.
Principal Investigator
AbbVie
Eligibility Criteria
This trial is for healthy men and women who are interested in helping to test a new drug called ALIA-1758, which could potentially be used for Alzheimer's disease. The details of the specific eligibility criteria have not been provided.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single ascending dose of ALIA-1758 or placebo
Follow-up
Participants are monitored for safety, tolerability, and pharmacokinetics after dosing
Treatment Details
Interventions
- ALIA-1758
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aliada Therapeutics
Lead Sponsor
AbbVie
Lead Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois